North America NGS Market (2025-2032)

The growth of the North America NGS market is mainly attributed to the rising prevalence of cancer, the increasing utilization of NGS in cancer research and treatment, the declining costs of sequencing procedures, advancements in sequencing technologies, the rising investments in pharmaceutical R&D, the increase in genome mapping programs, and the improvements in regulatory and reimbursement frameworks for NGS-based diagnostic tests. However, the high costs of NGS systems and consumables, the availability of alternative technologies, the low chances of identifying positive, actionable mutations for precision medicine, and ethical and legal issues related to NGS-based diagnosis restrain the growth of this market.

The increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to create growth opportunities for the players operating in the North America NGS market. However, the lack of skilled professionals and regulatory & standardization concerns in diagnostic testing are major challenges to market growth.

The increasing demand for NGS automation, the development of portable sequencing technologies, and increasing partnerships and collaborations among NGS instrument manufacturers to expand and improve product offerings are prominent trends in the North America next-generation sequencing market.

With rapid advancements in NGS technology, key players in this market actively collaborate to transform patients‘ lives by providing appropriate genetic variation and function analysis and ultimately delivering personalized healthcare. Many of these collaborations aim to improve bioinformatics and enhance technological capabilities for developing innovative products and solutions.

Some of the recent collaborations and partnerships are as follows:

• In January 2025, QIAGEN N.V. (Netherlands) partnered with Helix OpCo, LLC (U.S.), a population genomics and viral surveillance company. This partnership will trigger the adoption of next-generation sequencing companion diagnostics in hereditary diseases.

• In March 2025, QIAGEN N.V. (Netherlands) partnered with SOPHiA GENETICS (U.S.) to combine Next Generation Sequencing (NGS) strengths. This partnership will give customers an advantage over high-quality QIAGEN NGS preparation kits.

• In November 2022, Illumina, Inc. (U.S.) partnered with Twist Bioscience (U.S.) to produce an Exome 2.0 Plus panel for disease research. Through this partnership, Illumina will offer the Exome 2.0 Plus panel with its DNA library preparation reagents packaged as a kit.

• In February 2022, Beckman Coulter, Inc. (U.S.) collaborated with Illumina, Inc. (U.S.) to develop new applications for the Biomek NGeniuS System. Illumina will develop applications specifically designed for the Biomek NGeniuS liquid handler.

• In November 2021, Beckman Coulter, Inc. (U.S.) collaborated with Integrated DNA Technologies, Inc. (U.S.) to develop new applications for the Biomek NGeniuS System. Integrated DNA Technologies aims to make its NGS solutions more accessible to a broader array of labs by automating its NGS solutions on the Biomek NGeniuS System.

• In September 2021, Beckman Coulter, Inc. (U.S.) collaborated with Invitae Corporation (U.S.) to develop new applications for the Biomek NGeniuS System.

• In June 2021, QIAGEN N.V. (Netherlands) collaborated with Verogen Inc. (U.S.) to accelerate the automation of NGS library prep kits and expand the Biomek NGenuiS liquid handler applications. Also, through this collaboration, both companies cooperate to commercialize a broad menu of forensically validated workflows for NGS by combining QIAGEN’s QIAseq products with Verogen’s library preparation products, expertise, and automation solutions.

• In February 2021, Thermo Fisher Scientific, Inc. (U.S.) partnered with SPT Labtech Ltd (U.K.). Through this partnership, SPT Labtech will co-market Thermo Fisher’s NGS library preparation products, further reducing Thermo Fisher’s material and reagent requirements for high throughput genome sequencing.

Thus, increasing collaborations among vendors are expected to accelerate the adoption of NGS technology in North America.

The capacity to sequence genes from any organism, enabling clinical and research insights, has revolutionized public health. In line with this trend, portable handheld sequencing devices are paving the path for future market expansion, rendering sequencing more affordable, streamlined, and rapid, while eliminating the necessity for extensive clinical laboratories.

Real-time sequencing has enabled researchers and medical professionals with instant sequencing data and prompt decision-making capabilities. Portable nanopore-based sequencers are designed to sequence the entire genome for less than USD 1,000. This device guides the DNA sequence through a pore within a compact protein, known as a nanopore, which is integrated into a membrane. As the DNA molecule traverses the nanopore, it links the template with the complementary strand via the adaptor. This interaction initiates an electric current, commonly recorded and visualized graphically.

Real-time sequencing is gradually finding applications in disease characterization, the food industry, and healthcare for contaminant detection and plant genome analysis in crop processing. For instance, Ginkgo Bioworks, a biotech company based in Boston, employed a MinION nanopore sequencing device to identify toxic contaminants in a culture. This swift detection enabled operators to remove the harmful components, effectively salvaging the culture. Additionally, Madagascar scientists utilized portable DNA sequencing technology to swiftly identify the bacteria causing tuberculosis (TB) and its drug resistance profile within the country.

Moreover, portable sequencing devices have demonstrated their utility in the early detection of viruses like Ebola and Zika. According to Cornell University (U.S.), portable sequencing presents several advantages compared to benchtop sequencers. These portable devices are cost-effective, mobile, convenient, and designed for seamless operation in the field. Additionally, they leverage biochemical principles, facilitating the real-time transmission of raw signals as soon as DNA molecules are detected.